Market
What will be Roche's strategic focus post-Poseida acquisition by 2025?
2
Resolution / Starting Odds
Focus on cancer treatments • 25%
Focus on genetic engineering • 25%
Focus on both equally • 25%
Focus on other areas • 25%
Roche's strategic announcements and press releases
Story
Roche Completes $1.5 Billion Acquisition of Poseida Therapeutics, Securing 66% Stake by January 8
Jan 8, 2025, 12:15 PM
Roche Holdings AG has successfully completed its tender offer for Poseida Therapeutics, Inc., acquiring a 66% stake in the U.S. genetic engineering firm. The transaction, valued at approximately $1.5 billion, aims to enhance Roche's capabilities in developing new cancer treatments. The acquisition is set to finalize on January 8, 2025, following the completion of the tender offer, which saw significant participation from shareholders.
View original story
Similar markets
Other strategic move • 25%
Partnership with another biotech • 25%
Another acquisition in oncology • 25%
Focus on internal development • 25%
Expansion into new markets • 25%
No significant changes • 25%
Development of new products • 25%
Focus on existing products • 25%
Vertex Pharmaceuticals • 25%
Other Biopharma Companies • 25%
Biogen • 25%
Gilead Sciences • 25%
Multiple companies • 25%
No further acquisitions • 25%
Stoke Therapeutics • 25%
Another named biotech company • 25%
CTO • 25%
CFO • 25%
None • 25%
CEO • 25%
A company with late-stage drug development • 25%
Sage Therapeutics • 25%
A company with mid-stage drug development • 25%
A company with a marketed drug • 25%
No acquisitions completed • 25%
Multiple acquisitions completed • 25%
Successful acquisition of Sage Therapeutics • 25%
Successful acquisition of another biotech • 25%
GSK • 25%
Johnson & Johnson • 25%
Eli Lilly • 25%
Other • 25%
New partnership in vaccine development • 25%
No significant strategic move • 25%
Investment in new vaccine technology • 25%
Expansion of vaccine production • 25%
Infectious diseases • 25%
Cancer • 25%
Neurological disorders • 25%
Other • 25%
Pursue mergers or acquisitions • 25%
Increase investment in marketing existing drugs • 25%
Develop a new obesity drug • 25%
Focus on improving CagriSema • 25%